Elly R. Lee, MD

Phone: (949) 753-1663
elee@irvineclinical.com

IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

5/8/2017

Professional Experience

CEO, Medical Director, and Principal Investigator, 2005-Present
Irvine Center for Clinical Research, Irvine, CA

Principal Investigator, Neuropsychiatry Unit, 2003-2005
Radiant Research/Irvine Center, Irvine, CA

Sub-Investigator, Neuropsychiatry and Medicine Unit, 2003-2005
Radiant Research/Irvine Center, Irvine, CA

Principal Investigator, Neuropsychiatry Unit, 2000-2003
Protocare Trials/Irvine Center for Clinical Research, Irvine, CA

Sub-Investigator, Neuropsychiatry and Medicine Unit, 1999-2003
Protocare Trials/Irvine Center for Clinical Research, Irvine, CA

Staff Psychiatrist, General Psychiatry (Outpatient), 1995-2000
Newport PsychCare Clinic, Newport Beach, CA

Staff Psychiatrist, General Psychiatry (Inpatient), 1993-1996
Orange County Community Hospital, Buena Park, CA

Certification and Licensure

- American Board of Psychiatry and Neurology: Board Eligible
- California Medical Board License #A52179 (Exp. 1/31/2019)
- DEA Certification (Exp. 3/31/2020)
- Good Clinical Practices: Compliance Annual Review and Investigator Meetings
- Human Participants Protection Education, HIPAA, OSHA Certificates
- Certified Rater: HAM-D17, HAM-D-24, HAM-D35, HAM-A, MADRS, MINI, CGI-I, CGI-S, C-SSRS, AIMS, BARS, SAS, MINI-Kids, CDRS-R, PANSS, YMRS, ADAS-Cog, ADCS-iADL, FAQ, MMSE, Ecog, NPI, BASQID, MHIS

Education and Training

Psychiatric Chief Resident (PGY IV), 1992-1993
Nassau County Medical Center / State University of New York, Stonybrook, East Meadow, NY

Psychiatric Resident (PGY I-III), 1989-1992
Nassau County Medical Center / State University of New York, Stonybrook, New York, NY

Clinical Research in Psychiatry, 1988-1989
Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY

MD, 1981
Institute of Medicine (I), Rangoon, Burma

Pre-Medical Training, 1976
Institute of Medicine (I), Rangoon, Burma

Elly R. Lee, MD

Phone: (949) 753-1663
elee@irvineclinical.com

2515 McCabe Way, Suite 350
Irvine, CA 92614

Professional Experience

CEO, Medical Director, and Principal Investigator, 2005-Present
Irvine Center for Clinical Research, Irvine, CA

Principal Investigator, Neuropsychiatry Unit, 2003-2005
Radiant Research/Irvine Center, Irvine, CA

Sub-Investigator, Neuropsychiatry and Medicine Unit, 2003-2005
Radiant Research/Irvine Center, Irvine, CA

Principal Investigator, Neuropsychiatry Unit, 2000-2003
Protocare Trials/Irvine Center for Clinical Research, Irvine, CA

Sub-Investigator, Neuropsychiatry and Medicine Unit, 1999-2003
Protocare Trials/Irvine Center for Clinical Research, Irvine, CA

Staff Psychiatrist, General Psychiatry (Outpatient), 1995-2000
Newport PsychCare Clinic, Newport Beach, CA

Staff Psychiatrist, General Psychiatry (Inpatient), 1993-1996
Orange County Community Hospital, Buena Park, CA

Certification and Licensure

- American Board of Psychiatry and Neurology: Board Eligible
- California Medical Board License #A52179 (Exp. 1/31/2019)
- DEA Certification (Exp. 3/31/2020)
- Good Clinical Practices: Compliance Annual Review and Investigator Meetings
- Human Participants Protection Education, HIPAA, OSHA Certificates
- Certified Rater: HAM-D17, HAM-D-24, HAM-D35, HAM-A, MADRS, MINI, CGI-I, CGI-S, C-SSRS, AIMS, BARS, SAS, MINI-Kids, CDRS-R, PANSS, YMRS, ADAS-Cog, ADCS-iADL, FAQ, MMSE, Ecog, NPI, BASQID, MHIS

Education and Training

Psychiatric Chief Resident (PGY IV), 1992-1993
Nassau County Medical Center / State University of New York, Stonybrook, East Meadow, NY

Psychiatric Resident (PGY I-III), 1989-1992
Nassau County Medical Center / State University of New York, Stonybrook, New York, NY

Clinical Research in Psychiatry, 1988-1989
Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY

MD, 1981
Institute of Medicine (I), Rangoon, Burma

Pre-Medical Training, 1976
Institute of Medicine (I), Rangoon, Burma

Elly R. Lee, MD

Phone: (949) 753-1663
elee@irvineclinical.com

IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

PROFESSIONAL AND ACADEMIC APPOINTMENTS

- Member of American Society of Clinical Psychopharmacology
- Member of Council of Chief Residents, Resident Selection, Utilization Review and Quality Assurance, Pertinence Review Committees, Nassau County Medical Center, 1992-1993
- Resident Representative of Hospitality Committee, Nassau County Medical Center, 1991-1992
- Preceptor to junior residents and medical students, SUNY Stonybrook, 1990-1993

CLINICAL TRIAL EXPERIENCE

Protocare Trials / Radiant Research (1999 to 2005)

1. XXXXX Versus Placebo in the Treatment of Generalized Anxiety Disorder. Principal Investigator
2. XXXXX Versus Placebo in Posttraumatic Stress Disorder. Principal Investigator
3. XXXXX Versus Placebo in the Treatment of Major Depression. (a) Principal Investigator
4. XXXXX Versus Placebo in the Treatment of Major Depression. (b) Principal Investigator
5. XXXXX Versus Placebo and XXXXX in the Acute Treatment of Major Depression. Principal Investigator
6. Efficacy Study of XXXXX in Patient With Panic Disorder. Sub-Investigator
7. Dose Finding Study in Patients With Major Depressive Disorder. Sub-Investigator
8. Monitor Long Term Safety of XXXXX in Major Depressive Disorder. Sub-Investigator
9. XXXXX Versus Placebo in Treatment of Major Depressive Disorder Resistant to XXXXX. Principal Investigator
10. Sustained Efficacy Study of XXXXX in Patients With Panic Disorder With or Without Agoraphobia. Principal Investigator
11. A Seven-Week, Multicenter Study to Examine Study Drug in Patients with Major Depressive Disorder Receiving XXXXX or XXXXX. Principal Investigator
12. Open Label XXXXX Rescue and Continuation Therapy Principal Investigator
13. Double Blind, Multicenter, Dose Finding Acute and Extension Study of XXXXX Versus XXXXX and Placebo in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator
14. Multicenter, 10 Week, Randomized, Double Blind, Placebo Controlled Flexible Dose, Outpatient Study of XXXXX in Children and Adolescents with Major Depressive Disorder. Principal Investigator
15. Multicenter, 24-Week Open Label Extension Study of XXXXX in Children and Adolescent Outpatients Previously Diagnosed with Major Depressive Disorder. Principal Investigator
16. XXXXX Versus Placebo in Childhood/Adolescent Depression. Sub-Investigator
17. Double Blind, Placebo Controlled Comparative Efficacy Study of XXXXX and XXXXX in Producing Remission in Outpatients with Major Depressive Disorder. Principal Investigator
18. Double Blind, Placebo-Controlled Study of XXXXX in Children and Adolescents with Generalized Anxiety Disorder. Sub-Investigator
19. A Randomized, Open Label, Parallel Groups, Outpatient Study To Examine the Long Term Safety and Tolerability of XXXXX for the Acute Treatment of Migraine in Adolescents. Sub-Investigator
20. A Phase II Randomized, Multicenter, Placebo-And-Active Controlled Study of Oral XXXXX in Subjects With Major Depressive Disorder. Principal Investigator
21. Phase III Contraception Study of XXXXX Subcutaneous Injection in Women of Childbearing Potential in the Americas (Including a Bone Mineral Density Substudy Comparing the Effects of XXXXX) Also Including a Return of Ovulation Substudy. Sub-Investigator
22. A Double-Blind, Placebo Controlled, Parallel Group, Flexible-Dose Study of XXXXX Extended Release Capsules in Adult Outpatients with Panic Disorder Principal Investigator

23. A Multicenter, Randomized, Double-Blind, Placebo Controlled Parallel – Group Trial To Assess the Efficacy of Oral XXXXX 2.5mg in the Acute Treatment of Migraine During the Mild Intensity Phase of an Attack in Patients Highly Disabled by Migraine (MIDAS Grades III or IV). Sub-Investigator
24. Flexible Dose Comparison of the Safety and Efficacy of XXXXX and Placebo in the Treatment of Generalized Anxiety Disorder. # 3570 Principal Investigator
25. A Randomized, Double-Blind, Placebo Controlled Parallel, Two-Week Efficacy and Safety of XXXXX in Subjects with Primary Insomnia. # 3703 Sub-Investigator
26. A Long Term Extension Study to Evaluate the Safety of Oral XXXXX in Subjects with Major Depressive Disorder. # 2927x1 Principal Investigator
27. A 12 Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Flexible Dosing of XXXXX at 500 to 1500 mg B.I.D. in the Treatment of Subjects with Painful Diabetic Neuropathy. #3612 Sub-Investigator
28. A Phase III , Vehicle-Controlled Study of XXXXX XXXXX Applied 2 Times per Week for 1 Week for Each Recurrence of Herpes Genitalis Over 12 Months. #3685 Sub-Investigator
29. Efficacy and Safety of a Flexible Dose of XXXXX versus Placebo in the Treatment of Psychosis in Alzheimer's Disease (#3583) Principal Investigator
30. A Well Controlled Safety and Efficacy Study of XXXXX in Subjects with Mild to Moderate Alzheimer's Disease (#3261) Principal Investigator
31. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of XXXXX 200 mg q.d., XXXXX 200 mg b.i.d. and Placebo in Patients With Treated Hypertension. (#3676) Sub-Investigator
32. A Dose Ranging Study of XXXXX in Patients With Primary Hypercholesterolemia. (# 3518) Sub-Investigator
33. A 12-Week, Randomized, Parallel, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of 4 Doses of XXXXX in Patient With Type 2 Diabetes (#3576) Sub-Investigator
34. A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of XXXXX and XXXXX in Hypertensive Patients with Type II Diabetes Mellitus. (#3535) Sub-Investigator
35. A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Impact on Quality of Life of 12 Weeks of XXXXX Therapy at Dosages of 200 and 300 mg Once Daily as Treatment for Adults With Excessive Sleepiness Associated with Shift Work Sleep Disorder, Followed by a 12-Month Open-Label Extension Period. (# 3643a1) Principal Investigator
36. A Double Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study Evaluating Three Dose Regimens of XXXXX, A Selective Alpha-Adrenergic Antagonist, In The Treatment of Benign Prostatic Hyperplasia (#3750) Sub-Investigator
37. A Phase III, Double-Blind, Randomized, Placebo Controlled Study of XXXXX in Severely Obese Subjects. (#3696)Sub-Investigator
38. An Open-Label Extension Study of the Safety and Efficacy of XXXXX in Patients With Generalized Anxiety Disorder. (#3597) Principal Investigator
39. A Double-Blind, Randomized, Placebo-Controlled, 3-Month Clinical Trial of XXXXX and XXXXX in the Treatment of Post Traumatic Stress Disorder (#3536). Principal Investigator
40. A 13-Week, International, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Trial Assessing the Safety and Efficacy of 2 Doses of XXXXX (200 mg and 400mg od) in Patients With Primary Knee Osteoarthritis, Using XXXXX (200 mg od) as a Comparator. (# 3753) Sub-Investigator
41. A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Efficacy and Safety of XXXXX (xxxxx HCl tablets) Sublingual (2 and 3 mg) In the Treatment of Male Erectile Dysfunction. (#3806) Sub-Investigator
42. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXXX in Subjects With Acute Migraine Attack. (#3844) Sub-Investigator

Elly R. Lee, MD
Phone: (949) 753-1663
elee@irvineclinical.com
IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

43. A Double-Blind, Placebo-Controlled, Parallel Group, Dose Response Study to Evaluate the Efficacy and Safety of XXXXX Versus Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy.(#1711) Sub-Investigator
44. Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy and Safety of Controlled Release XXXXX and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip (#3881) Sub-Investigator
45. A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of XXXXX/XXXXX as an Oral Contraceptive (#2390) Sub-Investigator
46. Double-Blind, Placebo-Controlled Study of Sustained Release XXXXXX in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency, and Urinary Incontinence (#3641) Sub-Investigator
47. A 6-Week, Double-Blind, Randomized, Multicenter, Fixed-Dose, Placebo-Controlled Study of XXXXX Dosed Once a Day in Patients With Generalized Anxiety Disorder (#3791) Principal Investigator
48. Evaluation of Safety and Efficacy of XXXXX in the Treatment of Chronic Pain in Patients With Painful Diabetic Neuropathy (#3758) Sub-Investigator
49. A Double-Blind, Randomized, Placebo-Controlled, 3-Month Clinical Trial of XXXXX and XXXXX in the Treatment of Post Traumatic Stress Disorder (#3635) Principal Investigator
50. A Double-Blind, Multicenter, Randomized, Parallel Group, Phase III Study to Evaluate the Safety and Efficacy of XXXXX in Comparison to XXXXX in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) (#2867) Sub-Investigator
51. A Double-Blind, Randomized, Placebo and Active Controlled, Parallel Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Once Daily Dose Oral Administration of 5 mg, 10 mg, 25 mg and 50 mg of XXXXXX for 8 Weeks in Subjects With Mild to Moderate Essential Hypertension (# 3913) Sub-Investigator
52. A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of XXXXX in Patients With Generalized Anxiety Disorder (GAD) (#3971) Principal Investigator
53. A Phase III, Double-Blind, Randomized, Placebo Controlled Study of XXXXX in Overweight and Obese Subjects With a 12-month Open-Label Extension Phase. (#3696) Sub-Investigator
54. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Continuation of Benefit of Two Dosages of XXXXX Complex for the Prophylactic Treatment of Migraine Headaches. (#2372x2) Sub-Investigator
55. A Prospective, Multinational, Double-Blind, Randomized, Active Controlled Trial in Patients With Essential Hypertension to Compare the Effect of XXXXX 80 mg and 160 mg, With or Without the Addition of XXXXX, One Daily to That of XXXXX 5 and 10 mg once daily, With or Without the Addition of XXXXX, on Cardiovascular Morbidity and Mortality. (#2338) Sub-Investigator
56. A Multicenter, Prospective, Randomized, Double-Blinded, Parallel Group Study Comparing the Effects of XXXXX (5/20 mg) to XXXXX (5mg) and XXXXX (20mg) on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension. (#3980) Sub-Investigator
57. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of XXXXX When Added to Ongoing Therapy with an HMG-CoA Reductase Inhibitor in Patient With Primary Hypercholesterolemia, Known Heart Disease or Multiple Cardiovascular Risk Factors (#3452) Sub-Investigator
58. A Double-Blind, Multicenter, Placebo- and Active- Controlled Acute and Extension Study of XXXXX in the Treatment of Major Depressive Disorder With Melancholic Features (#3925) Principal Investigator
59. 12 Week, Multinational, Multicenter, Controlled, Open, 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiority Between Pre and Post-Meal Administration of XXXXX and Pre-Meal Regular Human Insulin in Subjects With Type 1 Diabetes Mellitus Receiving Insulin XXXXX as the Basal Insulin Therapy (# 3974) Sub-Investigator

60. Clinical Protocol For A Double-Blind, Randomized, Parallel Group Comparison Study of the Safety of XXXXX Vs XXXXX in Treated Hypertensive Patients With Osteoarthritis (# 3871) Sub-Investigator
61. A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of Evaluating Efficacy and Safety of Three Doses of XXXXX (5mg, 10mg, and 20mg) Versus Placebo in Patients With Major Depressive Disorder (# 3920) Principal Investigator
62. A Randomized, Double-Blind, Comparator-Controlled Study of XXXXX Vs XXXXXX in the Treatment of Subjects With Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA1) (#4055) Sub-Investigator
63. A Phase III, Open-Label Safety and Efficacy Study of XXXXX in Outpatients with ADHD, Ages 6 to 18 Years. (#2474) Principal Investigator
64. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of XXXXX in Obese Patients With Untreated Dyslipidemia (#3813) Sub-Investigator
65. Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity (#3783a1) Sub-Investigator
66. A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study to determine the Efficacy, Safety, Tolerability and Pharmacokinetic of XXXXX in Patients With Type 2 Diabetes Mellitus (# 3833) Sub-Investigator
67. A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel Group Evaluation of the Efficacy of XXXXXX 50 mg Tablets versus Placebo in the Treatment of Self-Described and/or Physician Diagnosed Sinus Headaches that Meet International Headache Society (IHS) Criteria for Migraine Headaches (# 4147) Sub-Investigator
68. Open-Label Extension Study of Sustained Release XXXXX in Subjects With Symptoms of Overactive Bladder (# 3641x1) Sub-Investigator
69. A 52-Week, Open-Label, Multicenter Study of the Long-Term Safety and Efficacy of XXXXX 200 mg T.I.D. in Patients With Constipation-Predominant and Alternating-Type Irritable Bowel Syndrome (# 4159) Sub-Investigator
70. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study With a Withdrawal Phase to Investigate the Safety and Efficacy of XXXXX 200 mg T.I.D. or 200 mg B.I.D. in Female Patients with Constipation-Predominant Irritable Bowel Syndrome (# 3633) Sub-Investigator
71. Long-Term, Open-Label, Safety Study of XXXXX in Patients 6 Years and Older (# 3552) Principal Investigator
72. Evaluation of Atherosclerotic Outcomes with XXXXXX Therapy (# 3832) Sub-Investigator
73. A Multicenter, Double-Blind, Randomized, Placebo-and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of XXXXX in Patients with Metabolic Syndrome and Dyslipidemia. (#4011) Sub-Investigator
74. Efficacy and Safety of XXXXX in Patient with Probable Alzheimer's Disease (#3822) Principal Investigator
75. Efficacy and Safety of XXXXX in Patients with Mild Cognitive Impairment (#3823) Principal Investigator
76. A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study to Evaluate the Efficacy and Safety of XXXXX in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase. (#2328) Sub-Investigator
77. A Phase III/IV Extension – A Phase III, Parallel, Randomized, Multicenter, Open-Label Clinical Study to Evaluate the Safety of XXXXX Extended Oral Contraceptive Therapy – 84-Day Active Cycle (#2745x1) Sub-Investigator
78. A Double-Blind, Placebo-Controlled, Parallel Group Design Dose-Ranging Study of Three Doses of XXXXX vs. Placebo for the Treatment of Sexual Dysfunction (Arousal Disorder) in Postmenopausal Women (# 4100) Principal Investigator

Elly R. Lee, MD
Phone: (949) 753-1663
elee@irvineclinical.com
2515 McCabe Way, Suite 350
Irvine, CA 92614

79. A Double-Blind, Placebo-Controlled, Parallel Group Design Dose-Ranging Study of Three Doses of XXXXX vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Disorder) in Postmenopausal Women (#4101) Principal Investigator
80. A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing the Percentage of Patients Achieving Low Density Lipoprotein Cholesterol Target with XXXXX Starting Doses of 10 mg, 20 mg, 40 mg, and 80 mg.(# 4168) Sub-Investigator
81. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXXXX Tablets in Patients with Primary Hypercholesterolemia (# 3713) Sub-Investigator
82. A Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXXXX Versus Over-Encapsulated XXXXX in Subjects with Acute Migraine Attacks (#4293) Sub-Investigator
83. A Phase III, Multi-Center, Randomized, Double-Blind, Parallel Group Study of XXXXX 20 mg, XXXXX 40 mg and Placebo in Patients with Multiple Moderate or Severe Acute Migraine Headaches (# 3695) Sub-Investigator
84. A Randomized, Double-Blind, Dose Ranging, Placebo-Controlled Trial to Determine the Lipid-Lowering Efficacy and Safety of XXXXX Alone and in Combination with XXXXX in Subjects with Mixed Dyslipidemia (# 4204) Sub-Investigator
85. A Multi-Center, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing the Percentage of Patients Achieving Low Density Lipoprotein Cholesterol Target with XXXXX Starting Doses of 10mg, 20mg, 40mg and 80mg (#4168) Sub-Investigator
86. A Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXXXX Versus Over-Encapsulated XXXXX in Subjects with Acute Migraine Headaches (#4293) Sub-Investigator
87. A Phase III, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of Combination Oral Contraceptive Regimens Utilizing Ethinyl Estradiol During the Pill-Free Interval for Prevention of Pregnancy in Women. (#4330) Sub-Investigator
88. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of the Hormone Replacement Therapy Combination Drug Product XXXXX in Postmenopausal Women with Concomitant Disease and Medication Known to Potentiate the Risk of Hyperkalemia. (#4300) Sub-Investigator
89. A Randomized, Double-Blind, Multi-Center Study to Assess the Safety of Long-Term Administration of Two Dose Levels of XXXXX in Patients with Primary Insomnia. (#3930) Sub-Investigator
90. A Randomized, Double-Blind, Multi-Center, Fixed-Dose, Cross-Over Study to Investigate the Efficacy and Safety of 20mg of XXXXX Given on Demand in Comparison to 100mg of XXXXX Given on Demand in Males with Erectile Dysfunction and a Diagnosis of Diabetes Mellitus and/or Hypertension and/or Hyperlipidemia. (#3521) Sub-Investigator
91. An Open Label Study of Topical XXXXX 0.01% Gel Applied 2 Times per Week for 3 Weeks for Each Recurrence of Herpes Genitalis over 52 Weeks. (#4347) Sub-Investigator
92. Randomized, Double-Blind, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of Monthly Oral Administration of 100mg and 150mg XXXXX with 2.5 mg Daily Oral XXXXX in Postmenopausal Osteoporosis. (#4267) Sub-Investigator
93. Randomized, Double-Blind, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of Two IV XXXXX Dose Regimens (2mg q 2 mo., 3mg q 3mo.) with 2.5mg Daily Oral XXXXX in Postmenopausal Osteoporosis. (#4266) Sub-Investigator
94. A Multicenter, Double-Blind, Randomized, Parallel Group, 28-Week Study to Evaluate the Efficacy and Safety of XXXXX and XXXXX Co-Administration Versus XXXXX in Patients with Hypercholesterolemia. (#4223) Sub-Investigator
95. An Open-Label Extension of Study DEX-MD-02A to Investigate the Long-Term Safety and Efficacy of XXXXX 200mg T.I.D. in Female Patients with Constipation-Predominant Irritable Bowel Syndrome. (#3663x1) Sub-Investigator

Elly R. Lee, MD

Phone: (949) 753-1663
elee@irvineclinical.com

IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

96. A Multinational, Randomized, Double-Blind, Parallel Group, Placebo Controlled 24 Week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 g/day) in Women with Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy Who Have Undergone Hysterectomy and Bilateral Oophorectomy. (#1727) Sub-Investigator
97. A Multinational, Randomized, Double-Blind, Parallel Group, Placebo-Controlled 24-Week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 g/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder on Concurrent Oral Hormone Replacement Therapy. (#4337) Sub-Investigator
98. A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Two Dose Levels (5mg and 20mg) of XXXXX Nasal Spray in the Acute Treatment of a Single Migraine Attack in Adolescent Migraineurs (12-17 Years of Age). (#4452) Sub-Investigator
99. A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (1950 mg/day and 3900 mg/day) in the Treatment of Osteoarthritis of the Hip or Knee. (#4360) Sub-Investigator
100. A Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of XXXXX Including 3-Months of Initial Drug Dosing, a 9-Month Off-Drug Treatment Period, and a 3-Month Re-Exposure Followed by a 3-Month Crossover in Overweight and Obese Subjects. (#4456) Sub-Investigator
101. A Randomized, Double-Blind, Multicenter, Positive Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of XXXX and XXXX Administered in Combination Compared to XXXX Alone in Hypertensive Patients Not Adequately Controlled with XXXX Alone. (#4525) Sub-Investigator
102. A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Tolerability and Efficacy of 12-Week Oral XXXX 100, 400, & 600 mg Twice Daily in the Prophylaxis of Migraine Headache Attacks. (#4567) Sub-Investigator
103. Clinical Protocol for a Double-Blind, Placebo Controlled, Randomized Two Week Comparison Study of the Efficacy and Tolerability of XXXX 10mg QD and XXXX 25 mg QD in Relieving the Signs and Symptoms of Osteoarthritis of the Knee. (#4588) Sub-Investigator
104. A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of XXXX 90 mg q.d. vs. XXXX Sodium 50 mg t.i.d. in Patients with Osteoarthritis. (#4281) Sub-Investigator
105. The Efficacy, Onset of Effect, and Safety of XXXX Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score. (#4478) Sub-Investigator
106. A Phase III Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral XXXX versus XXXX in Subjects with Gout. (#4630) Sub-Investigator
107. An international, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, 52-week GI clinical safety study to demonstrate that XXXX (400mg od) reduces the risk to develop complicated ulcers as compared to NSAIDs (XXXX 500mg bid and XXXX 800 mg tid), in osteoarthritis patients. (#4269) Sub-Investigator
108. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of XXXX Nasal Spray in the Acute Treatment of Adult Subjects with Migraine. (#4641) Sub-Investigator
109. An 8-week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Fixed Dose Study Comparing the Efficacy and Safety of XXXX or XXXX to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. (#4688) Principal Investigator
110. Open-Label, Long-Term, Multicenter Study of Safety and Tolerability if XXXX 40-60 mg in the Acute Treatment of Migraine in Adults. (#3695x1) Sub-Investigator
111. Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The Study-Extension Safety Study. (#4579) Sub-Investigator

Elly R. Lee, MD
Phone: (949) 753-1663
elee@irvineclinical.com
IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

112. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Combination with XXXX vs. XXXX Alone in Subjects with Active Rheumatoid Arthritis and Inadequate Response to XXXX. (#4447) Sub-Investigator
113. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy Trial of the Use of XXXX in the Treatment of Patients with Bipolar Depression. (#4372) Principal Investigator
114. Double-Blind, Randomized, Active Comparator Parallel Group Comparison Study of the Safety of XXXX, XXXX, and XXXX in Treated Hypertensive Patients with Osteoarthritis. (#4910) Sub-Investigator
115. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Three Dose Groups of XXXX in Patients with Neuropathic Pain Due to Diabetic Neuropathy. (#4936) Sub-Investigator
116. A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX in Pediatric Depression. (#4888) Principal Investigator
117. A Randomized, Double-Blind, Multi-Center, Parallel-Group, Three Month Study to Compare the Tolerability and Efficacy of Flexible Dose XXXX Versus Placebo in Men with Erectile Dysfunction and Depression. (#4771) Principal Investigator
118. An Open-Label Study of XXXX for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied with Rizatriptan Therapy. (#4926) Sub-Investigator
119. The Efficacy, Onset of Effect, and Safety of XXXX Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International. (#4478) Sub-Investigator
120. An 8 –Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed Dose Study Comparing the Efficacy and Safety of XXXX to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. (#4688) Principal Investigator
121. A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of XXXX in Children and Adolescents Ages 6-17 with Oppositional Defiant Disorder. (#4971) Principal Investigator
122. A Double-Blind, Placebo-Controlled study to Evaluate the Efficacy of MT100 in the Early Treatment of Headaches in Subjects with Migraine (#5073) Sub-Investigator
123. A Phase III, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral XXXX in Subject with Gout. (#4879) Sub-Investigator
124. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of XXXX in Combination with XXXX Compared to XXXX Plus Placebo for 24 weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Non-TZD Oral Monotherapy. (#5099) Sub-Investigator
125. A Muliticenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral XXXX (20-40-60mg) Versus Placebo In Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period. (#5103) Principal Investigator
126. A Four-Arm Study Comparing the Analgesic Efficacy and Safety of XXXX Once a Day 100, 200, 300 mg Versus Placebo for the Treatment of Pain due to Osteoarthritis of the Knee. (#4705) Sub-Investigator
127. Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled for Patients on XXXX and Open Label Patients on XXXX, Comparative Study in Patients with Type II Diabetes. (#5030) Sub-Investigator
128. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study to Evaluate the Efficacy and Safety of XXXX at Dosages up to 16mg/day, in the Treatment of Chronic Post-Traumatic Stress Disorder in Adults. (#5097) Principal Investigator
129. A Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Safety and Efficacy Study of XXXX in Adolescents Aged 13-17 with Attention Deficit Disorder (ADHD). (#202561) Principal Investigator

130. A Double-Blind, Randomized, Prospective Trial to Evaluate the Efficacy and Safety Adjunctive XXXX versus Placebo in Subjects with Major Depressive Disorder with Suboptimal Response to Standard Antidepressant Therapy (#203503) Principal Investigator
131. A Double-Blind, randomized, Prospective, Study to Evaluate Adjunctive XXXX versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy (#203504) Principal Investigator
132. Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of XXXX in the Acuter Treatment of Migraine Headaches (#203281) Sub-Investigator
133. An Open-Label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine Over 12 Months (#203393) Sub-Investigator
134. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8 Week, Safety and Efficacy Study of XXXX 3 mg Compared to Placebo in Subjects with Insomnia Related to Major Depressive Disorder (#203240) Sub-Investigator
135. A Randomized, Double-Blind Comparison of Placebo and XXXX XXXX Given Once a Day in Adults with Attention-Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Function. Principal Investigator
136. A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for XXXX (XXXX 85 mg/XXXX Sodium 500mg) Administered during the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks. Principal Investigator
137. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Demonstrate the Safety and Efficacy of Daily 0.3mg Synthetic Conjugated Estrogens, A (XXXX) for the Treatment of Vasomotor Symptoms in Postmenopausal Women. Sub-Investigator
138. A Double-Blind, Randomized, 6-Month Evaluation of the Efficacy of Topical XXXX in Hysterectomized Women with Female Sexual Arousal Disorder. Principal Investigator
139. A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of the 28-Day Oral Contraceptive XXXX. Principal Investigator
140. A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase Study of the Efficacy and Safety of XXXX XXXX Release (XXXX) in Combination with an Antidepressant in the Treatment of patients with Major Depressive Disorder with Inadequate Response to an Antidepressant Treatment. Principal Investigator
141. A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of XXXX Plus XXXX (XXXX), XXXX alone or XXXX alone in Subjects with Type 2 Diabetes. Sub-Investigator
142. A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of XXXX (XXXX) in Subjects with Type 2 Diabetes. Sub-Investigator

Irvine Center for Clinical Research (2005 to Present)

AbbVie

143. Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX in Subjects with Early Alzheimer's Disease. Principal Investigator. 2017 to Present

Allergan

144. A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy, Safety and Tolerability of Multiple Dosing Regimens of Oral XXXX in Episodic Migraine Prevention. (Protocol xxxx) Principal Investigator. 8/16 to Present

Amgen

145. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of (xxxx) in Migraine Prevention. (Protocol xxxx) Principal Investigator. 7/15 to Present

Ardea Biosciences

146. Long Term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (xxxx). (Protocol xxxx) Sub-Investigator. 9/11 to 5/13
147. A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of xxxx and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol. (Protocol xxxx) Sub-Investigator. 12/11 to 8/14
148. New-A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of xxxx Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Contraindication to a xxxx Inhibitor . (Protocol xxxx) Sub-Investigator. 2/12 to 11/13
149. A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of xxxx and xxxx Compared to xxxx Alone at Lowering Serum Uric Acid and Resolving Tophi Subjects with Tophaceous Gout. (Protocol xxxx) Sub-Investigator. 1/12 to 7/14
150. A Long-Term Open Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study to Lesinurad Monotherapy in Subjects with Gout. (Protocol xxxx) Sub-Investigator. 6/12 to 7/14
151. A Long-Term Extension Study of Lesinurad in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol. (Protocol xxxx) Sub-Investigator. 1/13 to present
152. A Long-Term Extension Study of Lesinurad in Combination with Febuxostat for Subjects with Gout Completing an Efficacy and Safety Study of Lesinurad and Febuxostat. (Protocol xxxx) Sub-Investigator 3/13 to present
153. A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of xxxx Monotherapy in Subjects with Gout. (Protocol xxxx) Sub-Investigator 8/13 to 7/14

Astra-Zeneca LP

154. A multi-center, double-blind, randomized, parallel-group, placebo-controlled, Phase III study of the efficacy and safety of xxxx sustained release (xxxxSR) in combination with an antidepressant in the treatment of patients with Major Depressive Disorder with inadequate response to an antidepressant treatment (Protocol xxxx) Principal Investigator. 12/06 to 9/07
155. A multicenter, randomized, placebo-controlled, double-blind, parallel group, Phase II study of 2 oral dose groups of xxxx, with a xxxx arm, in subjects with Generalized Anxiety Disorder (Protocol xxxx) Principal Investigator. 1/09 to 5/09
156. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Long-Term Safety and Tolerability Study of xxxx as a Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy. (Protocol xxxx) Principal Investigator. 6/10 to 3/12
157. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of xxxx as an Adjunct to an Antidepressant in Patients with Major Depression Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. (Protocol xxxx) Principal Investigator. 6/10 to 4/11
158. A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of xxxx 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction of Stroke in Patients with Type 2 Diabetes Mellitus [xxxx – effect of xxxx on Health outcomes in Diabetes Mellitus patients Intervention Study] Sub-Investigator. (Protocol xxxx) 7/14 to Present

AR Scientific, Inc.

159. A multi-center, randomized, placebo-controlled, double-blind, parallel group, 1-week,dose-comparison study to evaluate the efficacy, safety and tolerability of xxxx in patients with an acute gout flare xxxx (Protocol xxxx). Sub-Investigator. 6/07 to 11/07

Avanir

160. A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of XXXXX for the treatment of agitation in patients with dementia of Alzheimer's type. (Protocol xxxx) Principal Investigator. 8/16 - Present

Bayer Healthcare Pharmaceuticals

161. Pivotal Phase III trial to investigate the efficacy and safety of an Orodispersible tablet xxxx versus placebo in the treatment of men with erectile dysfunction (ED) – a fixed-dose, double-blind, randomized multi-center trial – xxxx. (Protocol xxxx) Principal Investigator. 4/08 to 1/09
162. A multi-center, randomized, double-blind, active-controlled, parallel group, 2-arm study to show superiority of the oral contraceptive xxxx over xxxx on hormone withdrawal-associated symptoms after 6 cycles of treatment. (Protocol xxxx)Principal Investigator. 8/08 to 10/09.

BioCryst Pharmaceuticals, Inc.

163. A Phase 2, Randomized, Double-Blind, Dose Ranging, Two-Part, Multi-Center Study to Evaluate the Urate-Lowering Activity and Safety of Oral xxxx Administered in Subjects with Gout. (Protocol xxxx) Sub-Investigator. 11/09 to 9/10
164. A Randomized, Double-Blind, Multi-Center Placebo Controlled, Combination Study to Evaluate the Urate Lowering Activity, Safety and Potential Phamacokinetic Interaction of Oral xxxx and xxxx Administered in Subjects with Gout. (Protocol xxxx) Sub-Investigator. 5/10 to 11/10
165. A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral xxxx Added to xxxx in Subjects with Gout Who Have Not Adequately Responded to xxxx Monotherapy. (Protocol xxxx) Sub-Investigator. 12/10 to 2/12
166. A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral xxxx Added to xxxx in Subjects with Gout and Concomitant Moderate Renal Insufficiency. (Protocol xxxx) Sub-Investigator. 9/11 to 8/12

Boehringer-Ingelheim Pharmaceuticals

167. A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of xxxx 50 milligrams daily and, with uptitration, 100 milligrams daily in post-menopausal women with hypoactive sexual disorder. (Protocol xxxx) Principal Investigator. 7/06 to 4/08
168. A Twelve Month, Open-Label, Safety Trial of xxxx 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire Disorder. (Protocol xxxx) Principal Investigator. 3/06 to 10/09
169. A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of xxxx (100 milligrams) administered orally once daily in naturally postmenopausal women in hypoactive sexual desire disorder in the United States. (Protocol xxxx)Principal Investigator. 09/09 to 1/11
170. A twenty-four week, randomized, double-blind, placebo controlled, safety and efficacy trial of xxxx (100 milligrams) administered orally once daily in premenopausal women with hypoactive sexual desire disorder in the United States. (Protocol xxxx)Principal Investigator. 09/09 to 3/11
171. Qualitive interview study to categorize men with low sexual desire and related distress. (Protocol xxxx) Principal Investigator. 2/10 to 6/10.
172. A twenty-eight week, open-label, safety, extension trial of xxxx (100 milligrams) daily in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder in North America. (Protocol xxxx) Principal Investigator. 2/10 to 1/11.
173. A randomized, double-blind, placebo-controlled parallel group efficacy and safety trial of xxxx (10 and 25 mg administered orally once daily) over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycaemic control despite a background therapy of xxxx alone or in combination with Metformin. (Protocol xxxx) Sub-Investigator. 9/10 to 4/11

Bristol Myers Squibb Company

174. A multi-center, randomized, placebo-controlled, double-blind, parallel group, Phase 3 trial to evaluate the efficacy and safety of xxxx (xxxx) in combination with xxxx Therapy in subjects with Type 2

Diabetes who have inadequate glycemic control on xxxx therapy alone (Protocol xxxx) Sub-Investigator. 2/06 to 6/06

175. A 4-week, multi-center, randomized, placebo-controlled, double-blind, parallel group, Phase 3 trial to evaluate the efficacy and safety of xxxx in comparison to Placebo as add-on treatment to Metformin XR in subjects with Type 2 Diabetes who have inadequate glycemic control with diet and exercise and as table dose of Metformin XR >/= 1500 mg/day. (Protocol xxxx) Sub-Investigator. 11/08 to 10/09

Cephalon, Inc.

176. A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Evaluate the Efficacy and Safety of xxxx at 4, 8, and 12 mg/day in the treatment of Adults with Generalized Anxiety Disorder. (Protocol xxxx/US) Principal Investigator. 8/05 to 4/06
177. A 12-Month, Open-Label, Flexible-Dosage study to Evaluate the Safety Efficacy of xxxx Treatment (up to 16mg/day) in Adults with generalized anxiety Disorder. (Protocol xxxx/US) Principal Investigator. 8/05 to 9/06

DOV Pharmaceuticals

178. A multi-center, standard of care-controlled study to evaluate the long-term safety of xxxx for the treatment of chronic low back pain. (Protocol xxxx) Principal Investigator. 8/05 to 10/07

Duramed Research

179. A Randomized, Multi-center, Double-Blind, Placebo-Controlled Trial to Demonstrate the Safety and Efficacy of Daily 0.3mg Synthetic Conjugated xxxx, A (xxxx) for the Treatment of Vasomotor Symptoms in Postmenopausal Women. (Protocol xxxx) Principal Investigator. 8/06 to 6/07
180. A prospective, multi-center, open-label study to evaluate the safety and efficacy of the 28-day oral contraceptive DR-1021 (Protocol xxxx). Sub-Investigator. 8/06 to 12/08

Eisai Medical Research, Inc.

181. A randomized, double-blind parallel study of xxxx Extended-release 50 mg versus xxxx 40 mg for healing and symptomatic relief of moderate to severe Erosive Gastroesophageal Reflux Disease (GERD) (Protocol xxxx). Sub-Investigator. 3/08 to 10/09
182. A randomized, double-blind parallel study of xxxx Extended-release 50 mg versus xxxx 40 mg for healing and symptomatic relief of mild to moderate Erosive Gastroesophageal Reflux Disease (GERD) (Protocol xxxx). Sub-Investigator. 3/08 10/09
183. A randomized, double-blind parallel study of xxxx Extended-release 50 mg versus xxxx 150 mg for maintenance of healed Erosive Gastroesophageal Reflux Disease (GERD) (Protocol xxxx). Sub-Investigator. 3/08 to 10/09

Forest Research Institute

184. Fixed dose comparison of xxxx to active comparator in moderate-to-severely depressed patients. (Protocol xxxx) Principal Investigator. 7/06 to 10/07
185. A double-blind, fixed-dose study of xxxx in adult patients with Major Depressive Disorder (Protocol xxxx) Principal Investigator. 4/08 to 4/09
186. A long-term, open-label extension study of xxxx in adult patients with Major Depressive Disorder
187. (Protocol xxxx) Principal Investigator. 4/08 to 9/09
188. A randomized, double-blind, placebo- and active-controlled study of the safety and efficacy of xxxx in patients with Diabetic Peripheral Neuropathic pain. (Protocol xxxx) Sub-Investigator. 1/09 to 10/09
189. A double-blind, placebo-controlled study of xxxx (xxxx) as adjunctive therapy in Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 3/09 to 7/10
190. A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of xxxx ER in Adolescent Patients with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 5/15 to Present

GlaxoSmithKline

191. A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with xxxx (0.5mg) and xxxx (0.4mg), administered once daily for 4 years, alone and in combination on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia. (Protocol xxxx) Sub-Investigator. 8/05 to 4/09
192. A multi-center, randomized, double-blind, double-dummy, parallel group, placebo-controlled study to investigate the efficacy, safety and tolerability of Oral xxxx capsules (2.5, 5, 10, 15 and 20 mg once a day) as monotherapy (diet and / or exercise treated) or as an add-on to Metformin for 16 weeks duration in subjects with Type 2 Diabetes Mellitus. (Protocol xxxx) Sub-Investigator. 3/06 to 12/06
193. A randomized, double-blind, single migraine attack, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and tolerability of xxxx (xxxx / xxxx) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrheal. (Protocol xxxx) Principal Investigator. 3/06 to 12/06
194. A Randomized, Double-Blind, Multi-Center, placebo-controlled, cross-over study to determine the consistency of response for xxxx (xxxx 85 mg / xxxx 500 mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks. (Protocol xxxx) Principal Investigator. 11/05 to 9/06
195. A Long-Term Safety Study of a Combination Product Containing xxxx and xxxx and for the Treatment of Migraine in Adolescents. (Protocol xxxx) Sub-Investigator. 10/07 to 3/09
196. A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of xxxx Modified Release Formulation (xxxx) with xxxx (xxx-XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients. (Protocol xxxx) Sub-Investigator. 5/06 to 6/08
197. A randomized, open-label, parallel-group, multicenter study to determine the efficacy and long term safety of xxxx compared with insulin subjects with Type 2 Diabetes Mellitus. (Protocol xxxx) Sub-Investigator. 7/09 to 6/11
198. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determined the efficacy and safety of xxxx when used in combination with xxxx with or without Metformin in subjects with Type 2 Diabetes Mellitus. (Protocol xxxx) Sub-Investigator. 7/09 to 6/11
199. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the efficacy and safety of two dose levels of xxxx compared with placebo in subjects with Type 2 Diabetes Mellitus. (Protocol xxxx) Sub-Investigator. 7/09 to 2/10
200. A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of xxxx as Compared with xxxx in Subjects with Type 2 Diabetes Mellitus.(Protocol xxxx) Sub-Investigator 5/10 to 1/12

Integrium

201. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of xxxx 75 mg bid to Placebo in patients with Stage I or Stage II Hypertension (Protocol xxxx) Sub-Investigator. 2/07 to 5/07

Intra-Cellular Therapies

202. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXXXX in the Treatment of Agitation in Patients with Dementia. (Protocol xxxx) Principal Investigator. 6/16 to Present

Lilly

203. Long-Term Open-Label, Safety Study of xxxx HCL in Patients, 6 Years and Older, with Attention Deficit Disorder. (Protocol xxxx) Sub-Investigator. 8/05 to 3/08
204. A Randomized, Double-Blind Comparison of Placebo and xxxx Given Once a Day in Adults with Attention-Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Function. (Protocol xxxx) Principal Investigator. 7/06 to 7/07

205. TRY FIRST: A 12-week, randomized, open-label trial of xxxx versus Generic SSRIs in the treatment of a severe Depressive episode. (Protocol xxxx) Principal Investigator. 3/08 to 6/09
206. A Double-Blind, Efficacy and Safety Study of xxxx versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. (Protocol xxxx) Principal Investigator 3/10 to 12/11
207. Long-Term, Open-Label, Safety Study of xxxx 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment. (Protocol xxxx) Principal Investigator. 8/10 to 9/12
208. A Study of xxxx in the Treatment of Men with Erectile Dysfunction. (Protocol xxxx) Sub-Investigator. 11/10 to 1/12
209. A Randomized, Placebo-Controlled, Double-Blind Study of xxxx Fixed Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective xxxx Reuptake Inhibitor Treatment . (Protocol xxxx) Principal Investigator. 1/12 to 1/14
210. A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% on Symptoms of Ejaculatory Dysfunction in Men with Testosterone Deficiency. (Protocol xxxx) Sub-Investigator. 5/12 to 4/14
211. A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men. (Protocol xxxx) Sub-Investigator. 3/13 to 11/15
212. The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin with Exetimibe to Evaluate LDL-C Lowering in Patients with Primary Hyperlipidemia (Protocol xxxx) Sub-Investigator. 9/14 to 3/16
213. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of xxxx in Patients with Episodic Migraine-the EVOLVE-1 Study. (Protocol xxxx) Principal Investigator. 12/15 to Present
214. Effect of XXXXX on Alzheimer's Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia. (Protocol xxxx) Principal Investigator 6/16 to Present
215. Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States. Principal Investigator.
216. Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials. By Avid Radiopharmaceuticals, a subsidiary of Lilly. Principal Investigator.

Merck

217. A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel-Group Efficacy and safety extension study of xxxx 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia. (Protocol xxxx) Principal Investigator. 8/05 to 10/06
218. A Phase IIa, multi-center, randomized, placebo-controlled clinical trial to study the safety and efficacy of xxxx for Migraine Prophylaxis in patients with episodic migraine. (Protocol xxxx) Principal Investigator. 11/08 to 5/09
219. A Phase 3, Safety and Efficacy Study of xxxx/xxxx xxxx/xxxx in Chronic HCV Genotype 1 IL28BCC Subjects. (Protocol xxxx) Sub-Investigator. 3/13 to 10/13

Novartis

220. A 52-week, international, multi-center, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of xxxx 100mg od, xxxx 100mg od and xxxx 200 mg od in patients with primary osteoarthritis of hip, knee, hand or spine. (Protocol xxxx) Sub-Investigator. 8/05 to 7/06
221. An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of xxxx 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension. (Protocol xxxx and xxxxE) Principal Investigator. 11/06 to 3/09

222. An 8-week, double-blind, multi-center, randomized, multi-factorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of xxxx administered alone and in combination with xxxx in patients with essential hypertension. (Protocol xxxx) Sub-Investigator. 1/09 to 2/09
223. A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of xxxx modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes. (Protocol xxxx) Sub-Investigator. 02/09 to 1/12

Ortho McNeal Neurologics, Inc.

224. Long-term, open-label safety study of oral xxxx 12.5 mg in the treatment of Migraine in adolescents. (Protocol xxxx) Principal Investigator. 1/06 to 6/06

Otsuka

225. xxxx Ophthalmic Suspension in the Treatment of Dry Eye: A Multi-center, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52-week Study. (Protocol xxxx) Principal Investigator. 7/05 to 4/07
226. A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral xxxx/xxxx Combination Therapy in Patients With Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 7/10 to 2/12
227. A Multicenter, 52-week, Open-Label Study to Assess the Safety and Tolerability of an Oral xxxx/xxxx Combination Therapy in Patients With Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 8/10 to 2/12
228. A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Trial of Flexible-dose xxxx (xxxx) as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 3/13 to present
229. A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral xxxx as Adjunctive Therapy in Adults with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 4/13 to Present

Pfizer

230. Prospective randomized evaluation of xxxx integrated safety vs. Ibuprofen or Naproxen – A Randomized, double-blind, parallel-group study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing xxxx with Naproxen and Ibuprofen. (Protocol xxxx) Sub-Investigator. 11/06 to 6/07
231. An 8-week, Randomized, Phase 2, Double-Blind, Sequential, Parallel-Group, Comparison Study of Two Dose Levels of xxxx Compared to Placebo as an Adjunctive Treatment in Outpatients with Inadequate Response to Standard of Care for Generalized Anxiety Disorder. (Protocol xxxx) Principal Investigator. 10/14 to 6/15
232. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Analgesic Efficacy and Safety of a Dose Titration Regimen for the Subcutaneous Administration of XXXX in Subjects with Osteoarthritis of the Hip or Knee. (Protocol xxxx) Sub-Investigator. 4/2016 to Present
233. A Phase 3, Multicenter, Long-term Observational Study Of Subjects From XXXXX Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement. Sub-Investigator

Procter & Gamble

234. A Phase III multinational, Randomized, Double-Blind, Placebo-Controlled Multi-Center study to Evaluate the Efficacy and safety of transdermal xxxx 300 mcg/day for 24 weeks and safety for a further 28 week Open-label period in Women with hypoactive sexual desire disorder on concurrent estrogen replacement therapy who have undergone hysterectomy and bilateral oophorectomy. (Protocol xxxx) Principal Investigator. 7/05 to 9/07
235. A randomized, double-blind, placebo-controlled, parallel-group, multi-center, 52-week study to evaluate the efficacy and safety of transdermal patches delivering 150 or 300 mcg/day xxxx in

menopausal women with low libido not receiving systemic estrogen or estrogen progestin therapy. (Protocol xxxx) Principal Investigator. 7/05 to 9/07

Roche

236. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study Of XXXXX In Patients With Prodromal To Mild Alzheimer'S Disease. Principal Investigator. 2017 to Present

Daiichi Sankyo

237. A multi-center, randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of xxxx in type 2 diabetes with inadequate glycemic control on Sulphonylurea Monotherapy or Sulphonylurea therapy in combination with other oral anti-diabetic agents. (Protocol xxxx) Sub-Investigator. 7/05 to 12/06
238. A multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of xxxx in type 2 diabetes with inadequate Glycemic Control on Metformin Monotherapy or Metformin in combination with other oral anti-diabetic agents. (Protocol xxxx) Sub-Investigator. 7/05 to 12/06
239. A multi-center, 52-week, open-label extension study to evaluate the long-term safety and tolerability of xxxx in type 2 diabetic patients. (Protocol xxxx) Sub-Investigator. 7/05 to 12/06
240. A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of xxxx as monotherapy for Type 2 Diabetes Mellitus. (Protocol xxxx) Sub-Investigator. 2/09 to 6/10

Sanofi Aventis

241. An eight-week, multi-center, randomized, double-blind, placebo-controlled study with xxxx as an active control, to evaluate the efficacy, safety and tolerability of a xxxx 100 mg dose once daily, in patients with Generalize Anxiety Disorder. (Protocol xxxx) Principal Investigator. 9/06 to 1/07
242. A multi-center, randomized, 24-52 week, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of xxxx 100 mg once daily in the prevention of relapse of depressive symptoms in out-patients with Major Depressive Disorder who achieved an initial response to 12 weeks of open-label treatment with xxxx 100 mg once daily dosing. (Protocol xxxx) Principal Investigator. 12/05 to 5/08
243. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, multi-center 12-week Study assessing the efficacy and safety of xxxx in patients with Type 2 Diabetes not treated with anti-diabetic agents. (Protocol xxxx) Sub-Investigator. 8/08 to 12/09
244. A Randomized, Open-label, Active-Controlled, 2-arm Parallel-Group, multi-center 24-week Study followed by an extension assessing the efficacy and safety of xxxx versus xxxx on top of Metformin in patients with Type 2 Diabetes not adequately controlled with Metformin. (Protocol xxxx) Sub-Investigator. 8/08 to 3/11
245. A multi-center, Randomized, Placebo-Controlled, "factorial" design, 12-month Study to evaluate the efficacy and safety of xxxx 25 mg/day and 50 mg/day co-administered with all registered xxxx strengths ranging from 10 mg to 80 mg in patients with primary hypercholesterolemia. (Protocol xxxx) Sub-Investigator. 8/08 to 6/09

Schering-Plough

246. A phase 2 randomized, double-blind, dose-response efficacy and safety study of xxxx compared to placebo in subjects with primary Hypercholesterolemia (familial and nonfamilial) or mixed hypercholesterolemia. (Protocol xxxx) Sub-Investigator. 09/09 to 7/10

Sepracor Inc.

247. The efficacy of xxxx 3 mg as adjunctive therapy in subjects with insomnia related to Generalized Anxiety Disorder. (Protocol xxxx) Principal Investigator. 8/05 to 11/06

248. Double-blind, randomized, placebo-controlled study examining the safety, efficacy and tolerability of xxxx in subjects with Major Depressive Disorder (including Atypical and Melancholic features). (Protocol xxxx) Principal Investigator. 11/07 to 6/09.

Shire

249. A Phase 2, Multicenter, Double-blind, Paralled-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of xxxx in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant. (Protocol xxxx) Principal Investigator. 12/11 to 3/14
250. A Phase 3, Open-label Multicenter, 12-month Extension Safety and Tolerability Study of xxxx in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Residual Symptoms or Inadequate Response Followi9ng Treatment with an Antidepressant. (Protocol xxxx) Principal Investigator. 12/11 to 5/14
251. A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of xxxx in Subjects Aged 6-17 years with Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP). (Protocol xxxx) Principal Investigator, 10/12 to 4/13

TauRX Therapeutics, Ltd

252. Exploratory Case-Controlled, Longitudinal Biomarker Study in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia and Untreated Matched Controls. (Protocol xxxx) Principal Investigator. 6/16 - Present

TAP Pharmaceuticals (Abbott Laboratories / Takeda)

253. A phase 3, open-label, randomized, Allopurinol-controlled study to assess the long-term safety of Oral xxxx in subjects with gout. (Protocol xxxx) Sub-Investigator. 8/05 to 4/07
254. A Phase 3 Study to Evaluate the Efficacy and Safety of xxxx (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD). (Protocol xxxx) Sub-Investigator. 11/05 to 10/06
255. A Phase 3, Open-Label Study to Assess the Long-Term Safety of xxxx (60mg QD and 90mg QD). (Protocol xxxx) Sub-Investigator. 11/05 to 10/06
256. A Phase 3 Study to Evaluate the Efficacy and Safety of xxxx (60mg QD and 90 mg QD) and an Active Comparator, xxxx (30 mg QD) on Healing of Erosive Esophagitis. (Protocol xxxx) Sub-Investigator. 11/05 to 3/07
257. A Phase 3 Study to Evaluate the Safety and Efficacy of xxxx (60mg QD and 90mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis. (Protocol xxxx) Sub-Investigator. 11/05 to 10/06
258. A Phase 3 Study to Evaluate the Safety and Efficacy of xxxx (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis. (Protocol xxxx) Sub-Investigator. 4/06 to 3/07
259. A Phase 3 Study to Evaluate Efficacy and Safety of xxxx (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease. (Protocol xxxx) Sub-Investigator. 4/06 to 3/07
260. A Phase III, Randomized, Multi-center, Double-blind, Allopurinol-controlled Study Assessing the Efficacy and Safety of Oral xxxx in Subjects with Gout. (Protocol xxxx) Sub-Investigator.12/06 to 4/08.
261. A phase 2 double-blind study to evaluate the safety and efficacy of xxxx (5mg QD, 20 mg QD, and 40 mg QD) and an active comparator, xxxx (30 mg QD) on healing of Erosive Esophagitis. (Protocol xxxx) Sub-Investigator. 4/07 to 7/08

Elly R. Lee, MD

Phone: (949) 753-1663
elee@irvineclinical.com

IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

Takeda

262. A multi-center, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of the combination of xxxx (xxxx) and Pioglitazone HCL (Actos) in subjects with Type 2 Diabetes. (Protocol xxxx) Sub-Investigator. 4/06 to 11/07
263. A multi-center, double-blind study to determine the efficacy and safety of the combination of xxxx plus Pioglitazone HCL (Actos), SYR-322 alone or Pioglitazone HCL alone in subjects with Type 2 Diabetes. (Protocol xxxx) Sub-Investigator. 4/06 to 4/08
264. A long-term, open-label extension study to investigate the durability of response and long-term safety of xxxx (xxxx) in subjects with Type 2 Diabetes. (Protocol xxxx) Sub-Investigator. 4/06 to 3/09
265. A randomized, double-blind, placebo-controlled, parallel group study to demonstrate the subjective treatment effects of xxxx on sleep using a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) in an "at-home setting" in an adult population with chronic insomnia. (Protocol xxxx). Principal Investigator. 4/07 to 9/07
266. A randomized, double-blind, parallel-group, placebo-controlled, active-referenced, fixed-dose study comparing the efficacy and safety of 2 doses of xxxx in acute treatment of adults with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 4/08 to 3/10
267. A long-term, open-label, flexible-dose, extension study evaluating the efficacy and safety of xxxx in acute treatment of adults with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 4/08 to 7/09
268. A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of single dose of xxxx in acute treatment of adults with Generalized Anxiety Disorder. (Protocol xxxx) Principal Investigator. 5/08 to 7/09
269. A phase 3, double-blind, randomized, factorial, efficacy and safety study of xxxx plus xxxx fixed- dose combination in subjects with moderate to severe Hypertension. (Protocol xxxx) Sub-Investigator. 1/09 to 6/10
270. A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of xxxx versus Placebo on Renal Function in Gout Subjects with Hyperuricemia and Moderate to Severa Renal Impairment. (Protocol xxxx) Sub-Investigator. 2/10 to 2/12
271. A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of xxxx versus Placebo in Joint Damage in Hyperuricemic Subjects with Early Gout. (Protocol xxxx) Sub-Investigator. 2/10 to 12/13
272. A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of xxxx and xxxx in Subjects With Gout and Cardiovascular Comorbidities. (Protocol xxxx) Sub-Investigator. 4/10 to Present
273. A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of xxxx in Acute Treatment of Adults with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 7/10 to 4/12
274. A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of xxxx (15 and 20 mg) in Subjects With Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 8/10 to 9/13
275. A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of xxxx in Combination with xxxx 100 mg in Subjects with Type 2 Diabetes Mellitus. (Protocol xxx) Sub-Investigator. 7/11 to 11/12
276. A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of xxxx 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects with Hyperuricemia and Hypertension. (Protocol xxxx) Sub-Investigator. 2/12 to 10/14

Elly R. Lee, MD

Phone: (949) 753-1663
elee@irvineclinical.com

IRVINE CLINICAL RESEARCH
2515 McCabe Way, Suite 350
Irvine, CA 92614

277. A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, xxxx-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of xxxx in Acute Treatment of Adults with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 11/11 to 4/12
278. A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of xxxx vs xxxx on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective xxxx Reuptake Inhibitor–Induced Sexual Dysfunction. (Protocol xxxx) Principal Investigator. 5/11 to 2/14
279. A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of xxxx 40mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout. (Protocol xxxx) Sub-Investigator. 4/2014 to present
280. A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of xxxx 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment. (Protocol xxxx) Sub-Investigator. 12/2014 to present
281. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of xxxx (5, 10 and 20 mg) in Adults with Major Depression Disorder. (Protocol xxxx) Principal Investigator. 2/16 to Present

Teva

282. A multicenter, open-label study to evaluate the efficacy and safety of a combination oral contraception regimen (xxxx) for the prevention of pregnancy in women. (Protocol xxxx) Principal Investigator. 09/09 to 8/11

Tioga

283. A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of xxxx in Subjects with Irritable Bowel Syndrome. (Protocol xxxx) Sub-Investigator. 3/06 to 10/07

Transcept Pharmaceuticals

284. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Efficacy and Safety of xxxx Lozenge in Adult Subjects with Insomnia Characterized by Difficulty Returning to Sleep after Awakening in the Middle-of-the-Night (MOTN). (Protocol xxxx) Principal Investigator. 4/07 to 12/07

Vivus

285. A double-blind, randomized, 6-month evaluation of the safety and efficacy of topical xxxx in hysterectomized women with female sexual arousal disorder (Protocol xxxx) Principal Investigator. 8/05 to 9/06

Watson Laboratories

286. A multi-center, randomized, double-blind, placebo-controlled, parallel evaluation of the efficacy and safety of xxxx in the treatment of the signs and symptoms of benign prostatic hyperplasia. (Protocol xxxx) Sub-Investigator. 8/05 to 6/06

Wyeth

287. A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed by a 6-Month Continuation Phase (Open-Label or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of xxxx versus xxxx in Postmenopausal Women with Major Depressive Disorder. (Protocol xxxx) Principal Investigator. 8/07 to 4/08

STATE OF CALIFORNIA
dca
DEPARTMENT OF CONSUMER AFFAIRS

The Medical Board of California
2005 Evergreen Street, Suite 1200
Sacramento, CA 95815

PHYSICIAN AND SURGEON

CERTIFICATE NO. **A52179** EXPIRATION **01/31/2019**

ELLY R LEE
2515 MCCABE WAY STE 350
IRVINE CA 92614-9401

ORIGINAL ISSUANCE DATE
07/30/1993

RECEIPT NO.
100035678